Fondaparinux Sodium

Description

This page contains brief details about the drug fondaparinux sodium, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Fondaparinux sodium was initially approved by the United States Food and Drug Administration (FDA) for medical use on November 29, 2001.

Mechanism of Action of Fondaparinux Sodium

Fondaparinux sodium is an anticoagulant medication that inhibits a specific factor in the blood clotting cascade. Its mechanism of action involves blocking the activity of factor Xa, a crucial enzyme in the coagulation (blood clotting) pathway.

Uses of Fondaparinux Sodium

Fondaparinux sodium is a medication with several important uses in preventing and treating blood clotting disorders. It is primarily employed to reduce the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly in situations where clot formation is more likely, such as after orthopedic surgeries like hip or knee replacements. It is also utilized to manage acute coronary syndromes (ACS). In addition to its role in preventing these serious conditions, it can be part of the treatment regimen for established cases of DVT and PE, helping to reduce the size of existing blood clots and prevent the formation of new ones.

Fondaparinux Sodium Dosage available

Fondaparinux sodium is typically administered via subcutaneous injection. It is important to follow the dosing instructions as your healthcare provider recommends.